ArticleInternational journal of breast cancer2026
Establishment of Breast Cancer Organoids: A Systematic Review and Meta-Analysis.
Article in International journal of breast cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Establishment of Breast Cancer Organoids: A Systematic Review and Meta-Analysis.International journal of breast cancer · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Organoid culture has emerged as a promising model for studying normal and tumor tissues. Organoids may resemble their tissue of origin, allowing assessment of disease behavior and drug response. In breast cancer (BC), successful organoid establishment may depend on factors like time from tissue collection to culture, dissociation methods, and media composition, which may affect tumor growth and tissue similarity across culture passages. This systematic review and meta-analysis are aimed at assessing the success rate of BC organoid establishment and their similarity to parental tumors. Methods: Following PRISMA guidelines, we conducted an electronic search in PubMed, Embase, and Web of Science using terms related to "breast cancer" and "organoids". Heterogeneity was assessed by I2 (%), with forest plots for all studies and subgroups. A fixed-effects meta-analysis estimated the overall establishment rate with 95% confidence intervals. Results: We analyzed 59 full-text articles. Five culture media types and 37 added components were reported, most frequent EGF (80%), glutamine, FGF, R-spondin (66%, each), Y27632, and N-acetylcysteine (64%, each). Ten studies provided data on initial samples and established organoids, totaling 504 and 349, respectively, with an establishment rate of 71.34% (95% CI: 67.55-75.14), varying from 31.25% to 86.21%. By subtype, establishment rates were as follows: Luminal A (57.47%), Luminal B (72.51%), HER2+ (71.24%), and triple-negative (78.75). Concordance between receptor expression in tumors and organoids was observed, with kappa values of 0.692 for ER, 0.597 for PR, and 0.711 for HER2. However, positive receptor expression reverted to negative in 19%, 31%, and 28% of organoids for ER, PR, and HER2, respectively. Conclusion: Breast cancer organoids were successfully established from primary tumor samples, demonstrating good overall concordance in receptor expression with the original tumors. These findings support the feasibility of patient-derived organoids as translational models; however, continuous phenotypic characterization across passages is recommended.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.